213 related articles for article (PubMed ID: 33066346)
1. Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors.
Carreras-Planella L; Juega J; Taco O; Cañas L; Franquesa M; Lauzurica R; Borràs FE
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066346
[TBL] [Abstract][Full Text] [Related]
2. An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Rhone ET; Bardhi E; Bontha SV; Walker PD; Almenara JA; Dumur CI; Cathro H; Maluf D; Mas V
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063776
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
5. Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.
Carreras-Planella L; Cucchiari D; Cañas L; Juega J; Franquesa M; Bonet J; Revuelta I; Diekmann F; Taco O; Lauzurica R; Borràs FE
J Nephrol; 2021 Jun; 34(3):861-874. PubMed ID: 33275196
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
7. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling.
Diémé B; Halimi JM; Emond P; Büchler M; Nadal-Desbarat L; Blasco H; Le Guellec C
Transplantation; 2014 Jul; 98(2):195-201. PubMed ID: 24598938
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional profiling of belatacept and calcineurin inhibitor therapy in renal allograft recipients.
Vitalone MJ; Ganguly B; Hsieh S; Latek R; Kulbokas EJ; Townsend R; Sarwal MM
Am J Transplant; 2014 Aug; 14(8):1912-21. PubMed ID: 24954576
[TBL] [Abstract][Full Text] [Related]
9. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic concentrations of calcineurin inhibitors do not deregulate glutathione redox balance in human renal proximal tubule cells.
Ramazani Y; Knops N; Berlingerio SP; Adebayo OC; Lismont C; Kuypers DJ; Levtchenko E; van den Heuvel LP; Fransen M
PLoS One; 2021; 16(4):e0250996. PubMed ID: 33930094
[TBL] [Abstract][Full Text] [Related]
12. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.
Press RR; de Fijter JW; Guchelaar HJ
Curr Pharm Des; 2010; 16(2):176-86. PubMed ID: 20205663
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction.
Maluf DG; Dumur CI; Suh JL; Lee JK; Cathro EP; King AL; Gallon L; Brayman KL; Mas VR
Am J Transplant; 2014 May; 14(5):1152-1163. PubMed ID: 24698514
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
Morales JM
Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
[TBL] [Abstract][Full Text] [Related]
17. The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells.
Matz M; Lorkowski C; Fabritius K; Wu K; Rudolph B; Frischbutter S; Brakemeier S; Gaedeke J; Neumayer HH; Mashreghi MF; Budde K
Transpl Immunol; 2016 Nov; 39():18-24. PubMed ID: 27693310
[TBL] [Abstract][Full Text] [Related]
18. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
Bentata Y
Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation.
Fernando M; Peake PW; Endre ZH
Biomark Med; 2014; 8(10):1247-62. PubMed ID: 25525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
